BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21385928)

  • 1. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.
    Takayama T; Nagashima H; Maeda M; Nojiri S; Hirayama M; Nakano Y; Takahashi Y; Sato Y; Sekikawa H; Mori M; Sonoda T; Kimura T; Kato J; Niitsu Y
    Clin Cancer Res; 2011 Jun; 17(11):3803-11. PubMed ID: 21385928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.
    Higurashi T; Hosono K; Endo H; Takahashi H; Iida H; Uchiyama T; Ezuka A; Uchiyama S; Yamada E; Ohkubo H; Sakai E; Maeda S; Morita S; Natsumeda Y; Nagase H; Nakajima A
    BMC Cancer; 2012 Sep; 12():413. PubMed ID: 22992267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial.
    Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
    BMC Cancer; 2020 Oct; 20(1):1043. PubMed ID: 33121471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
    Higurashi T; Hosono K; Takahashi H; Komiya Y; Umezawa S; Sakai E; Uchiyama T; Taniguchi L; Hata Y; Uchiyama S; Hattori A; Nagase H; Kessoku T; Arimoto J; Matsuhashi N; Inayama Y; Yamanaka S; Taguri M; Nakajima A
    Lancet Oncol; 2016 Apr; 17(4):475-483. PubMed ID: 26947328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
    Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
    Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention of colorectal cancer.
    Niitsu Y; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Abe T; Kogawa T; Takahashi M; Matsunaga T; Kato J
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S40-3. PubMed ID: 15309513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
    Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant crypt foci of the colon as precursors of adenoma and cancer.
    Takayama T; Katsuki S; Takahashi Y; Ohi M; Nojiri S; Sakamaki S; Kato J; Kogawa K; Miyake H; Niitsu Y
    N Engl J Med; 1998 Oct; 339(18):1277-84. PubMed ID: 9791143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
    Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Number of aberrant crypt foci in the rectum is a useful surrogate marker of colorectal adenoma recurrence.
    Uchiyama T; Takahashi H; Endo H; Kato S; Sakai E; Hosono K; Yoneda M; Inamori M; Hippo Y; Nakagama H; Nakajima A
    Dig Endosc; 2012 Sep; 24(5):353-7. PubMed ID: 22925289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.
    Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
    BMC Cancer; 2020 Aug; 20(1):770. PubMed ID: 32807113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci.
    Kowalczyk M; Sigorski D; Dyśko Ł; Zieliński E; Zupanovich Lucka D; Klepacki Ł
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
    Meyskens FL; McLaren CE; Pelot D; Fujikawa-Brooks S; Carpenter PM; Hawk E; Kelloff G; Lawson MJ; Kidao J; McCracken J; Albers CG; Ahnen DJ; Turgeon DK; Goldschmid S; Lance P; Hagedorn CH; Gillen DL; Gerner EW
    Cancer Prev Res (Phila); 2008 Jun; 1(1):32-8. PubMed ID: 18841250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rectal aberrant crypt foci (ACF) as a predictor of benign and malignant neoplastic lesions in the large intestine.
    Kowalczyk M; Orłowski M; Klepacki Ł; Zinkiewicz K; Kurpiewski W; Kaczerska D; Pesta W; Zieliński E; Siermontowski P
    BMC Cancer; 2020 Feb; 20(1):133. PubMed ID: 32075595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant crypt focus size predicts distal polyp histopathology.
    Kim J; Ng J; Arozulllah A; Ewing R; Llor X; Carroll RE; Benya RV
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1155-62. PubMed ID: 18483337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural history of aberrant crypt foci.
    Schoen RE; Mutch M; Rall C; Dry SM; Seligson D; Umar A; Pinsky P
    Gastrointest Endosc; 2008 Jun; 67(7):1097-102. PubMed ID: 18178205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
    Limburg PJ; Mahoney MR; Ziegler KL; Sontag SJ; Schoen RE; Benya R; Lawson MJ; Weinberg DS; Stoffel E; Chiorean M; Heigh R; Levine J; Della'Zanna G; Rodriguez L; Richmond E; Gostout C; Mandrekar SJ; Smyrk TC;
    Cancer Prev Res (Phila); 2011 Feb; 4(2):259-69. PubMed ID: 21209397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
    Sandler RS; Halabi S; Baron JA; Budinger S; Paskett E; Keresztes R; Petrelli N; Pipas JM; Karp DD; Loprinzi CL; Steinbach G; Schilsky R
    N Engl J Med; 2003 Mar; 348(10):883-90. PubMed ID: 12621132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial.
    Higurashi T; Takahashi H; Endo H; Hosono K; Yamada E; Ohkubo H; Sakai E; Uchiyama T; Hata Y; Fujisawa N; Uchiyama S; Ezuka A; Nagase H; Kessoku T; Matsuhashi N; Yamanaka S; Inayama Y; Morita S; Nakajima A
    BMC Cancer; 2012 Mar; 12():118. PubMed ID: 22443173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.
    Sinicrope FA; Viggiano TR; Buttar NS; Song LMWK; Schroeder KW; Kraichely RE; Larson MV; Sedlack RE; Kisiel JB; Gostout CJ; Kalaiger AM; Patai ÁV; Della'Zanna G; Umar A; Limburg PJ; Meyers JP; Foster NR; Yang CS; Sontag S
    Cancer Prev Res (Phila); 2021 May; 14(5):573-580. PubMed ID: 33648940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.